Guangzhou Kingmed Diagnostics Group's declining ROCE trend is worrying, indicating potential loss of competitive edge or market share. Despite increased capital deployment, returns and sales are decreasing. High investor expectations are reflected in the 144% stock rise over five years, but current trends cast doubt on long-term performance.